Trial Watch reads new and updated studies on ClinicalTrials.gov and emails you only the trials that touch your drugs, your indications, or your competitors — phase, status, sponsor, and why it matters — in plain English.
A competitor’s Phase 3 readout, a new entrant in your drug class, a sponsor expanding into your indication — it’s all public on ClinicalTrials.gov, buried in half a million studies.
Drug or intervention names, conditions/indications, and competitor sponsors.
Each day we pull newly posted and updated studies, and score relevance against your list — by drug, condition, and sponsor.
A short email: the trial, its phase and status, who’s running it, and why it matters — with a link to the full record.
Phase, status, and sponsor pulled from the registry record, with the reason it reached you.
PublicRadar
Trial WatchThis morning
Medium
Competitor · Phase 3 · Active, not recruiting
A Phase 3 study (status: Active, not recruiting) led by Northgate Oncology, evaluating a pembrolizumab combination in NSCLC.
Why it matters to you. Pembrolizumab and NSCLC are both on your watchlist — a competitor advancing a combination into Phase 3 in your indication is a signal worth tracking for your own program and timelines.
Start free for 14 days. Cancel anytime.
$149/mo
Tell us your email and the drugs, conditions, or competitors you follow. We’ll have your watch live within a day.
Trial Watch surfaces publicly available data from ClinicalTrials.gov (a service of the U.S. National Library of Medicine) for informational and competitive-research purposes only. It is not medical or investment advice, and is neither produced nor endorsed by NIH, NLM, or the U.S. government. Always consult the underlying study record.